Martingale Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Martingale Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,801	Closed	-$649K	–	909
2020 Q4	$649K	Sell	3,801 -1,302	-26%	-$193K	0.01%	557
2020 Q3	$717K	Buy	5,103 +1,099	+27%	+$167K	0.01%	718
2020 Q2	$643K	Buy	+4,004	New	+$545K	0.01%	831
2019 Q2	–	Sell	-3,703	Closed	-$442K	–	1062
2019 Q1	$442K	Buy	+3,703	New	+$476K	﹤0.01%	900
2018 Q2	–	Sell	-10,607	Closed	-$786K	–	1013
2018 Q1	$786K	Buy	+10,607	New	+$707K	0.01%	762

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Martingale Asset Management's SRPT Position: Q1 2021 in Review

Martingale Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 3,801 shares — an estimated $649K sold.

Martingale Asset Management first reported a position in SRPT in Q1 2018 and held it in 5 quarters. The position peaked at $786K in Q1 2018. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

Martingale Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
Martingale Asset Management sold 3,801 Sarepta Therapeutics shares in Q1 2021, an estimated $649K.
Martingale Asset Management first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 5 quarters.
Martingale Asset Management's Sarepta Therapeutics position peaked at $786K in Q1 2018.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Martingale Asset Management's 13F filing for Q1 2021, filed 13 May 2021.